Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.23

+4.7%
HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

At a Glance

Live Snapshot
Market Cap$155.38M
EPS-1.6700
P/E Ratio-34.52
Earnings Date08/13/2026

uncy

Interest Expense

Last Annual Value

71.00K

3-Year CAGR

128%

5-Year CAGR

-22%

10-Year CAGR

%

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Competitors Analysis of Interest Expense

UNCY · NASDAQ
CompanyInterest Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
71.00K
-4.7%-35.3%N/A 
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
2.82M
25.0%13.8%4.6%
CBUS logo
Cibus, Inc.
NASDAQ:CBUS
35.48M
23.4%90.1%142.7%
8.71M
-11.4%-10.7%9.0%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
21.41K
-34.4%-29.0%N/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
293.00K
113.8%-19.4%41.2%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Fair Value Envelope

UNCY · NASDAQ

Our analysis suggests that UNCY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.23, this represents a potential HIDDEN relative to our calculated worth for Unicycive Therapeutics, Inc..

Intrinsic Value
Current Price: $7.23